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This is one of series of review articles on formaldehyde and formaldehyde-releasers (others: formaldehyde
in cosmetics, in clothes and in metalworking ﬂuids and miscellaneous). Thirty-ﬁve chemicals were
identiﬁed as being formaldehyde-releasers. Although a further seven are listed in the literature
as formaldehyde-releasers, data are inadequate to consider them as such beyond doubt. Several
(nomenclature) mistakes and outdated information are discussed. Formaldehyde and formaldehyde
allergy are reviewed: applications, exposure scenarios, legislation, patch testing problems, frequency
of sensitization, relevance of positive patch test reactions, clinical pattern of allergic contact dermatitis
from formaldehyde, prognosis, threshold for elicitation of allergic contact dermatitis, analytical tests
to determine formaldehyde in products and frequency of exposure to formaldehyde and releasers. The
frequency of contact allergy to formaldehyde is consistently higher in the USA (8–9%) than in Europe
(2–3%). Patch testing with formaldehyde is problematic; the currently used 1% solution may result in
both false-positive and false-negative (up to 40%) reactions. Determining the relevance of patch test
reactions is often challenging. What concentration of formaldehyde is safe for sensitive patients remains
unknown. Levels of 200–300 p.p.m. free formaldehyde in cosmetic products have been shown to induce
dermatitis from short-term use on normal skin.
Key words: contact allergy; formaldehyde; formaldehyde releaser; patch testing; review article;
threshold. © John Wiley & Sons A/S, 2009.
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Formaldehyde is a common cause of contact allergy.
In Europe, 2–3% of patients suspected of con-
tact dermatitis have positive patch test reactions,
and in the USA prevalence rates of sensitization of
8–9% are reported in this selected group of patients.
Allergic contact dermatitis caused by formalde-
hyde is often chronic, presumably because it is
difﬁcult to avoid exposure to the allergen com-
pletely. Indeed, formaldehyde may be found in
many cosmetics, toiletries, household products such
as washing and cleaning agents and in a great num-
ber of industrial applications including adhesives,
paints, lacquers and metalworking ﬂuids. Often,
the products are not preserved with formaldehyde
itself, but with agents that release formaldehyde
under usage conditions, the so-called formaldehyde-
releasers (or formaldehyde donors). Well-known
examples are quaternium-15, imidazolidinyl urea,
diazolidinyl urea, DMDM hydantoin and 2-bromo-
2-nitropropane-1,3-diol, preservatives frequently
used in cosmetic products. Industrial products such
as metalworking ﬂuids frequently contain formalde-
hyde donors, such as the Bioban® product range
of biocides and tris(N-hydroxyethyl) hexahydrotri-
azine (better known by its trade name Grotan® BK).
Other products containing and releasing formalde-
hyde are the formaldehyde resins including urea
formaldehyde and melamine formaldehyde resins.
These were formerly used extensively as textile64 DE GROOT ET AL. Contact Dermatitis 2009: 61: 63–85
Table 1. Data in the literature about formaldehyde-releasers that appear to be wrong or outdated (1–8)
Presented as formaldehyde releaser
(chemical name and/or trade name) Comments
Bakzid® P (mixture of cyclic amino-acetals and organic amine salts) The trade name Bakzid® P is probably not used currently.
However, some Bakzid® products contain the formaldehyde
releaser tris(N-hydroxyethyl) hexahydrotriazine
(triazinetriethanol)
Biocide® DS 5249 (1,2-benzisothiazolin-3-one + a formaldehyde
releaser)
Trade name currently not used
Dantoin MDMH (methylaldimethoxy-methan formal) Neither name can be identiﬁed
Forcide® 78 (mixture of triethylhexahydro s-triazine and
trihydroxyethylhexahydro s-triazine)
Forcide® 78 is the current trade name for
2-hydroxymethylaminoethanol-tri-N-ethylhydroxy-2-
aminomethylene
Glutaraldehyde Glutaraldehyde occasionally cross-reacts with formaldehyde, but
in the literature it is not found to be a formaldehyde releaser
Grotan® HD (N-methylol-chloracetamide) Grotan® HD is a current trade name for tris(N-hydroxyethyl)
hexahydrotriazine (triazinetriethanol)
Hexamidine Hexamidine in the literature is not a found to be a formaldehyde
releaser
Imidazolidinyl urea (Euxyl® K 200) Trade name Euxyl® K 200 is probably currently not used
KM 103 This name is probably currently not in use. There are, however,
various chemicals named KM followed by a number, of which
KM 200 (alcohol) contains the formaldehyde releaser
tris(N-hydroxyethyl) hexahydrotriazine (triazinetriethanol)
MDM hydantoin (Dantoin®, Dantoin® 685) Dantoin® is used as synonym for
1,3-dichloro-5,5-dimethylhydantoin and for phenytoin sodium.
The trade name Dantoin® 685 is probably currently not used
Parmetol®lK 5 0( N-methylol-chloracetamid, O-formal of benzyl
alcohol)
The name Parmetol® K 50 was only found as being a registered
trade name in Canada for a mixture of 13% chloroacetamide
and 7.3% paraformaldehyde (under the company Gray
Products)
Preventol® D1 (1-(3-chloroallyl)-3,5,
7-triaza-1-azoniaadamantanechloride benzyl formal)
Chemical name is incorrect, benzyl formal must be deleted. The
trade name Preventol® D1 is probably currently not in use
Preventol® D2 (benzylhemiformal) Preventol® D2 is in chemical databases used as a trade name for
1,1’-(methylenebis(oxymethylene)) bis-benzene, but also used
for benzylhemiformal
Preventol® D3 (chlormethylacylamino methanol) The trade name Preventol® D3 is probably currently not in use.
Chemical name chlormethylacylamino methanol cannot be
identiﬁed in chemical databases
Preventol® D3/D5 (N-methylol-chloracetamide) The trade names Preventol® D3 and D5 are probably currently
not in use
ﬁnishes and caused dermatitis from clothing in
formaldehyde-sensitive individuals due to their high
content of free formaldehyde. The ﬁnishes used
currently by the clothing manufacturers release far
less free formaldehyde, but are even today reported
as causes of clothing allergic contact dermatitis.
Lists of formaldehyde-releasers have been pub-
lished in articles and recent textbooks (1–8). Such
lists are commonly handed out to patients allergic
to formaldehyde with the instruction to avoid con-
tact with these chemicals and products containing
them. However, for most formaldehyde-releasers,
the current understanding of their relationship to
formaldehyde allergy appears to be limited and
mainly based on patch test studies. Thus, it is
often assumed that concomitant positive patch test
reactions to formaldehyde and a releaser or to
two or more releasers are caused by allergy to
formaldehyde, though deﬁnite proof of this is
often lacking (9–11). Whether it is really necessary
to avoid all formaldehyde-releasing preservatives
in patients allergic to formaldehyde is largely
unknown. Indeed, only with a few compounds
such as diazolidinyl urea (12) and imidazolidinyl
urea (13), have experimental use test exposure stud-
ies have been performed in patients allergic to
formaldehyde. Some authors have suggested that
for formaldehyde-sensitive patients, it is sufﬁcient
to avoid only those formaldehyde-releasers that, in
addition to formaldehyde, also elicited a positive
patch test reaction (14). Others, however, think that
it is prudent for formaldehyde-sensitive subjects to
recommend avoidance of products containing any
releaser (15–17).
The purpose of this study is to review the liter-
ature on the formaldehyde-releasers and their rela-
tionship to formaldehyde sensitivity with emphasis
on (i) frequency of sensitization, (ii) patch testContact Dermatitis 2009: 61: 63–85 FORMALDEHYDE AND FORMALDEHYDE-RELEASERS 65
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relationship to formaldehyde and other formalde-
hyde-releasers, (iii) the relevance of positive patch
test reactions, (iv) the amount of formaldehyde
released by the various chemicals and, consequently,
(v) the risk they pose for individuals allergic to
formaldehyde. Do we have adequate knowledge to
give formaldehyde allergic patients proper advice on
avoidance of formaldehyde-releasers?
This review is presented as a series. In this
article, formaldehyde sensitivity is reviewed, an
inventory of the formaldehyde-releasers is presented
and the frequency of their presence in various
product categories is summarized. In other parts,
formaldehyde-releasers commonly used in cosmetic
products are discussed, formaldehyde in textile ﬁn-
ishes is considered, and ﬁnally releasers in industrial
products, notably metalworking ﬂuids, and miscel-
laneous releasers are reviewed.
Identiﬁcation and Selection of
Formaldehyde-releasers
Formaldehyde-releasers were deﬁned as: (i) sub-
stances that release formaldehyde as a result of
decomposition and/or (ii) chemicals synthesized
from formaldehyde that may still contain residues
of free formaldehyde (e.g. melamine/formaldehyde
and urea-formaldehyde resins).
Reports on chemicals ascertained or claimed
to be formaldehyde-releasers were found in text-
books (1–3), reviews (4–8), case reports and origi-
nal articles. Exact identiﬁcation of some substances
described as formaldehyde-releasers has been prob-
lematic or even impossible, as a considerable num-
ber of synonyms and trade names are used in
the literature, without identifying active ingredi-
ents. Several frequently used trade names (also in
recent textbooks and patient information leaﬂets
found on the internet) currently appear to be out
of use or are applied to the wrong ingredients,
some chemical names could not be identiﬁed in
any database and some substances have incor-
rectly been identiﬁed as formaldehyde-releasers
(Table 1).
Included in this article are only those formalde-
hyde-releasers that could unequivocally or with a
high degree of certainty be identiﬁed, for instance,
by their Chemical Abstract Service Registry Num-
bers (CAS numbers) or their chemical structure.
Thus, a total of 42 formaldehyde-releasers were
found in the literature. These are presented alpha-
betically in Table 2 with their (suggested) com-
mon name (INCI name if existing), IUPAC name,
other synonyms, (some) veriﬁed trade names and
CAS numbers. Due to difﬁculties in identifying
some presumed formaldehyde-releasers in the lit-
erature data (4, 6, 18) as described above, this
list cannot be expected to be complete. Moreover,
7 of the 42 chemicals have been mentioned as
formaldehyde-releasers in one or more publications,
but data are inadequate to label them as such beyond
doubt (Table 2B). Over half of the formaldehyde-
releasers are commercially available for patch test-
ing (Table 3).
Not included in this review are:
(1) Compounds that may (possibly) cross-react to
formaldehyde, such as glutaraldehyde (21) and
glyoxal (22, 23).
(2) Chemicals in which formaldehyde may be
formed by air oxidation (e.g. polyoxyethylene
dodecyl alcohols) or degradation, but for which
no relevant clinical data are available (24, 25).
(3) Formaldehyde resins in which formaldehyde
allergy does not play an important role, such as
phenol-3 formaldehyde resins (26) and p-tert-
butyl phenolformaldehyde resin (27).
(4) Tosylamide/formaldehyde resin, a resin based
on toluenesulfonamide and formaldehyde, is
the major ingredient in most nail lacquers.
Free formaldehyde is present in the majority
of nail lacquers, with concentrations varying
from 0.02% to 0.5% (28). Despite this, the
allergen in nail lacquers appears to be the resin
itself and people do not become sensitized
to formaldehyde from the use of these nail
cosmetics: the amount of free formaldehyde
in ﬁnished, dried nail lacquer is believed to
be nil (29) and nail lacquers do not seem to
cause dermatitis in patients already allergic
to formaldehyde. This may be explained by
application of the resin to the nail (avoiding
contact with the skin), only very infrequent
application of the product and swift evaporation
of any free formaldehyde.
Formaldehyde
Formaldehyde (methanal) is a colourless gas with
a characteristic pungent odour. Formalin is a
37–40% aqueous solution of formaldehyde, to
which 10–15% methyl alcohol has been added to
inhibit polymerization (16). This simple aldehyde
is ubiquitous in the environment, and is generated
in and released from the smoke of burning wood,
coal, charcoal, tobacco, natural gas and kerosene.
Formaldehyde also occurs naturally in certain foods
such as coffee (especially instant coffee), dried
bean curd, cod ﬁsh, caviar, maple syrup, shiitake
mushrooms and smoked ham. It is an irritant as
well as an allergen and a potential respiratory
carcinogen (15). It can be formed by breaking, con-
version and oxidization of ingested aspartame (anContact Dermatitis 2009: 61: 63–85 FORMALDEHYDE AND FORMALDEHYDE-RELEASERS 71
Table 3. Formaldehyde-releasers commercially available for patch testing
Chemical Chemotechniquea Trolabb Brialc
Benzylhemiformal 1% pet. 1% pet.
Bioban® CS 1135 1% pet. 1% pet.
Bioban® CS 1246 1% pet. 1% pet. 1% pet.
Bioban® P 1487 0.5% pet. 1% pet. 1% pet.
2-Bromo-2-nitropropane-1,3-diol 0.25% pet. 0.5% pet. 0.5% pet.
Diazolidinyl urea 2% pet. 2% pet. 2% pet.
1,3-Dimethyl-4,5-dihydroxyethyleneurea 4.5% aqua
Dimethylol dihydroxyethyleneurea 4.5% aqua
Dimethylol dihydroxyethylene urea, modiﬁed 5% aqua
DMDM hydantoin 2% aqua 2% aqua 2% aqua
Ethylene urea 1% pet.
Ethylene urea, melamine formaldehyde mix 5% pet.
Formaldehyde 1% aqua 1% aqua 1% aqua
Imidazolidinyl urea 2% pet. 2% pet. 2% pet.
Melamine/formaldehyde resin 7% pet.
Methenamine (hexamethylenetetr a m i n e ) 2 %p e t . 1 %p e t . 1 %p e t .
N,N’-Methylenebis(5-methyloxazolidine) 1% pet. 1% pet.
N-Methylol-chloracetamide 0.1% pet.
Polyoxymethylene urea (urea-formaldehyde resin) 10% pet.
Quaternium−1 5 1 %a n d2 %p e t . 1 %p e t . 1 %p e t .
Tris(N-hydroxyethyl)hexahydrotriazine (triazinetriethanol, Grotan® BK) 1% aqua 1% pet. 1% pet.
Tris(hydroxymethyl)nitromethane (Tris Nitro) 1% pet. 1% pet.
aAvailable at: www.chemotechnique.se.
bAvailable at: www.hermal.com.
cAvailable at: www.brial.com.
artiﬁcial sweetener) and possibly causes migraines
in formaldehyde allergic individuals (30).
Applications and exposure
Formaldehyde can be used as a disinfectant because
it kills most bacteria and fungi. It was ﬁrst com-
mercially used in embalming ﬂuid and as a preser-
vative for laboratory specimens. Later, it was used
to make plywood and asphalt shingles. It has also
been added in bonded leather, waterproof glues, fer-
tilizers and photographic developers. Exposure to
formaldehyde is difﬁcult to estimate because the
chemical, besides being used as such, is incorpo-
rated into a large variety of products and reactants in
many chemical processes, including formaldehyde-
releasers, polymerized plastics, metalworking ﬂu-
ids (31, 32), medicaments, fabrics, cosmetics and
detergents (Table 4).
In ﬁnished products, there may be several sources
of formaldehyde, some of which are ‘hidden’ or
‘occult’ (16):
(1) formaldehyde added as an active ingredient for
preservation;
(2) formaldehyde released from formaldehyde
donors (usually preservatives);
(3) excess formaldehyde used to synthesize the
releaser;
(4) formaldehyde which is used for the preser-
vation of raw materials used to prepare the
product;
(5) formaldehyde in formaldehyde-based raw mate-
rials used to prepare the product;
(6) formaldehyde used to sterilize vessels for the
storage of raw materials or products;
(7) formaldehyde released by package materials
such as formaldehyde resins coating cosmetic
and pharmaceutical tubes (39, 40);
(8) formaldehyde formed in situ by degradation
of non-formaldehyde-containing components of
the product (41). Auto-oxidation of ethoxylated
alcohols, which are widely used in cleaners,
toiletries and laundry products, may lead to
the formation of formaldehyde (24). Polysor-
bate 80, a non-ionic surfactant present in many
cosmetic and pharmaceutical products, after
air oxidization was shown to cause formalde-
hyde formation in concentrations of 70–500
p.p.m. (42). Lower concentrations of 2.5–6
p.p.m. have been found with polysorbate 20,
40 and 60 (43).
Legislation in the EU
Exposure to formaldehyde in the EU is subject to
restrictions because of its toxicological properties.
The maximum allowed concentration in ﬁnished
products is 0.2%. Annex VI of Cosmetics Directive
76/768/EC further stipulates that all ﬁnished prod-
ucts containing formaldehyde or substances in this
Annex which release formaldehyde must be labelled
with the warning ‘contains formaldehyde’ where the
concentration of free formaldehyde in the ﬁnished72 DE GROOT ET AL. Contact Dermatitis 2009: 61: 63–85
Table 4. Examples of products that may contain formaldehyde
and applications (adapted from Andersen et al. (1),
Flyvholm (16, 33), Feinman (34) and Rietschel and Fowler (35))a
Adhesives (glues, pastes and cements)
Agricultural chemicals (seed disinfectants)
Antifreeze agents
Antiperspirants
Asphalt shingles
Binders (polymers)
Castings
Cellulose esters
Chipboard production
Cleaning products (36)
Clothing (wash and wear, crease-resistant)
Colouring agents
Construction materials
Corrosion inhibitors
Cosmetics (37)
Cutting ﬂuids (31, 32)
Dental preparations and dentifrices
Deodorizers
Disinfectants
Dry cleaning materials
Embalming ﬂuids
Explosives manufacture
Filling agents (stopping, putty, etc.)
Fish meal industry
Flame retardant
Flooring materials
Footwear (resins and plastics)
Fumigants
Hardeners
Hydrocarbons (e.g. oil)
Impregnating agents
Laboratory chemicals
Latex rubber
Medications: wart remedies, anhydrotics
Metal coatings (not paints)
Metal and tyre cleaners
Metalworking ﬂuids (31, 32)
Mildew preventatives (fruits and vegetables)
Mineral wool production
Orthopaedic casts
Paints, lacquers and coatings
Paint removers
Paper industry (38)
Phenolic resins in adhesives and footwear
Photographic paper and solutions
Plywood
Polishes and ﬁnishes
Printing inks
Starch (spray and powdered)
Surface active agents
Tanning agents
Textiles
Tissue ﬁxatives
Toiletries (33)
Urea plastics in adhesives and footwear
aThese applications have been reported in the literature, but we
have not checked whether formaldehyde may at this time indeed
be present in such products; some of the information may therefore
be outdated. The list is not intended to suggest that exposure may
cause clinically relevant reactions.
product exceeds 0.05 wt% (500 p.p.m.) (44). How-
ever, as has been shown above, there are many
‘hidden’ or ‘occult’ sources of formaldehyde, and
manufacturers may not be aware of such formalde-
hyde contamination.
Patch testing with formaldehyde
Patch testing with formaldehyde is not very reliable.
Formerly, test concentrations of 3–5% were used,
resulting in many false-positive reactions. Currently,
1% aqua is the standard for patch testing. However,
even this concentration may result in false-positive
reactions as less than 50% of positive reactions are
reproducible on retesting (45). Irritant, doubtful and
follicular reactions to formaldehyde also occur (46).
Conversely, false-negative reactions may not be
infrequent either (8, 46, 47). Trattner et al. tested
3734 patients with both 1% aqua and 2% aqua
between 1992 and 1996. A total of 121 of them had a
positive reaction to one or both test preparations. Of
98 patients who reacted to formaldehyde 2% aqua
(judged to be truly allergic reactions), only 59 (60%)
reacted to the currently used formaldehyde 1% aqua.
This may indicate that up to 40% of allergic patients
are missed when tested with formaldehyde 1% aqua
only (46).
Frequency of sensitization
Into the 1980s, prevalence rates of sensitization to
formaldehyde were high in the USA (48), Canada
(49), many European countries (50, 51) and Japan
(52). In Japan, from a high frequency of 18% in
1977, the frequency dropped to 2.8% a couple of
years later. This fall reﬂected its Government reg-
ulations which restricted the levels of formalde-
hyde allowed in underclothes to 75 p.p.m. or less
for adults and 15 p.p.m. or less for babies. Previ-
ously, garments had contained as much as 10 000
p.p.m. (52).
Formaldehyde per se was previously used as a
preservative in cosmetics, as a disinfectant, as an
antiperspirant and in textile ﬁnish resins releasing
large amounts of formaldehyde, resulting in high
sensitization rates (53). However, its use in cosmet-
ics has largely been abandoned and replaced with
formaldehyde donors due to allegations of carcino-
genicity. As a disinfectant, it was partly replaced by
other compounds such as glutaraldehyde and gly-
oxal. Also, low formaldehyde textile resins were
introduced. Thus, since the 1980s, there has been
a decline in the frequency of sensitization in most
countries. The decrease in patch test reactions may
also partly be explained by test procedures. In the
past, higher concentrations of formaldehyde than the
currently recommended 1% aqueous formaldehyde
solution were used for patch testing, which has prob-
ably resulted in more irritant reactions, erroneously
considered to represent truly positive allergic patch
test reactions.
Currently, the frequency of sensitization to forma-
ldehyde remains at a stable and relatively low level
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the general patch test population (Table 5). In the
USA, however, rates of 8–9% are rule rather than
exception.
From large-scale studies, it appears that women
are affected 1.2–1.5 times more frequently than
men. Table 5 summarizes the experience in routine
patch testing with formaldehyde back to 1990. The
older literature has been reviewed in Fransway and
Schmitz (11) and Fransway (29).
Relevance of positive patch test reactions to
formaldehyde
From the 29 studies summarized in Table 5, data
on relevance have been provided in eight (28%)
only. Remarkably, six of these studies (75%) were
performed in the USA. The percentages of patients
in whom the positive reaction to formaldehyde was
considered to be relevant have varied widely. The
highest percentage was 90% in a UK study, but this
was based on 14 patients only (69). In a Danish
study, relevance was assumed in 78% of patients
who were allergic to either 1% or 2% aqua (46).
In the USA studies, the positive patch test reac-
tions were considered to be relevant in 65–75% of
the cases. However, in ﬁve investigations performed
by the North American Contact Dermatitis Group
(NACDG), the percentages also included patients
with ‘possible relevance’. Possible relevance was
considered if the patient was exposed to circum-
stances in which the skin contact with materials
known to contain formaldehyde would likely occur
and the rash distribution and clinical situation ﬁt.
This could, also according to the authors themselves,
result in an overestimation of the true possible rel-
evance of the test allergen (68). Indeed, in only
12–33% of the cases were the reactions scored as
‘deﬁnite/probable’ relevance.
Currently, most reactions to formaldehyde are
believed to result from contact with cosmetics and
household products (46, 79) in which formaldehyde-
releasers are frequently used, especially in women.
Over half of 67 skin creams in Denmark investi-
gated in 2000 for the presence of preservatives, for
example, contained formaldehyde-releasers (80). A
1992 study of washing and cleaning agents showed
that formaldehyde-releasing compounds were am-
ong the most commonly used preservatives in
such products (36). Sensitization to formaldehyde
may also be caused by occupational exposure,
especially in metalworkers and the medical pro-
fessions (81–83). Occupational sensitization occurs
more frequently in men (81). The most detailed per-
tinent information has been published by Fransway
and Schmitz (11). These authors investigated 300
patients allergic to formaldehyde for the relevance of
their positive patch tests. In two-thirds of the cases,
formaldehyde sensitivity was assessed as a signiﬁ-
cant contributory or the single most causative factor
in the patient’s dermatosis. In these patients, a deﬁn-
able source of exposure to formaldehyde and tem-
poral consistency with dermatitis ﬂare were present.
29% had chronic dermatitis (including atopic der-
matitis) and were exposed to topical products con-
taining formaldehyde (releasers), 21% were primar-
ily sensitized to topical cosmetics, medicaments or
emollients. Occupational sensitization was seen in
43 patients (14%) in whom 12 were nurses, 6 med-
ical technicians, 7 beauticians and 7 machinists.
Clothing exposure accounted for only nine cases
(3%) (11).
Clinical pattern of allergic contact dermatitis from
formaldehyde
Patients allergic to formaldehyde are often women
with hand eczema with/without facial dermati-
tis (81, 84). This is explained by the hands being
exposed to household cleansing agents (e.g. wash-
ing-up liquids) where formaldehyde is often found
in combination with detergents that impair barrier
function and increase penetration (84). Facial der-
matitis may be caused by the application of cos-
metics containing formaldehyde (releasers). Hand
eczema from formaldehyde sensitivity is also found
more often in nurses and other medical profes-
sions (paramedicals) and in metal workers (29, 32,
82, 83).
Allergic contact dermatitis due to formaldehyde
released from textile permanent-press ﬁnished is
characterized by a distribution of lesions on skin
areas having direct contact with fabric, particularly
areas in which the garment moves over the skin
surface (the inner thigh, the neck [collars in men]),
and in the relatively moister locations of the body,
such as the periaxillary areas, groin, waist and
the antecubital and popliteal fossae. Widespread
eruptions may also be seen with sparing of the
hands and face, although in patients allergic to
formaldehyde these body parts may also be involved
from the use of cosmetics containing formaldehyde-
releasers (85).
Prognosis of formaldehyde allergic contact
dermatitis
As formaldehyde is so widely distributed in the
environment, it is difﬁcult to avoid. It may not
appear on labels, as formaldehyde can be present in
products as contaminants from ‘hidden’ or ‘occult’
sources, that manufacturers are unaware of. Many
patients ﬁnd it difﬁcult to read and correctly interpret
the labels of cosmetic products; they do not only74 DE GROOT ET AL. Contact Dermatitis 2009: 61: 63–85
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have to look for the name formaldehyde but also for
those of the formaldehyde donors (86). In addition,
it appears that labelling is not always reliable: in
5/67 creams purchased in Denmark, formaldehyde-
releasers were present but were not declared on the
label (80).
Indeed, in a group of 57 patients allergic to
formaldehyde and well-instructed how to avoid
products containing the allergen, 77% were still
exposed to formaldehyde at follow-up 1–5 years
later as shown by the analysis of the products
(cosmetics, washing powders, dishwashing liquids,
gloves and paper) brought in by them (84). Thus,
even in patients actively trying to avoid products
containing formaldehyde, the dermatitis will infre-
quently heal completely. Most patients will still suf-
fer from exacerbations of dermatitis (81, 84, 87),
though fewer in number than in those not paying
attention to their allergy (84).
Threshold for elicitation of contact allergic
reactions in patients allergic to formaldehyde
Patch test studies with formaldehyde and formalde-
hyde-containing products
In their now classic and often cited investigations,
Jordan et al. (88) performed double-blind controlled
studies on formaldehyde threshold
responses in nine allergic patients by repeated (three
times, day 0, day 3, day 5, ﬁnal reading at day
7) applications of patch tests at the same site in
the axilla for 1 week with formaldehyde 0, 30, 60
and 100 p.p.m. in a 12% methanol in water vehi-
cle. Five of them were selected on the basis of their
known strong allergy to formaldehyde. At day 3,
three patients had positive reactions to 100 p.p.m.
formaldehyde, two to 60 p.p.m. and one to 30 p.p.m.
More positive responses were observed 2 days later
(day 5) and at day 7 (2 days after the removal of
the third patch test materials): Four of nine patients
had positive reactions to 30 p.p.m., 5 out of 9 to 60
and 6 out of 9 to 100 p.p.m. Two subjects reacting
to 30 p.p.m. at 5 days were retested later and again
had positive reactions after 5 days. Four non-allergic
control subjects were negative (88).
The same protocol was later used to patch
test two commercial creams preserved with 0.1%
quaternium-15 (analysis with a polarographic me-
thod identiﬁed 100 p.p.m. free formaldehyde in
both) in the same nine patients. Cream A was pos-
itive already at day 3 in 3 out of 9 patients and
in 6 out of 9 at the ﬁnal reading at day 7. For
Cream B, these ﬁgures were 2 out of 9 and 5 out of
9, respectively. These results closely corresponded
to the patch tests with solutions of 60–100 p.p.m.
formaldehyde in methanol/aqua.
Flyvholm et al. (89) patch tested 20 patients aller-
gic to formaldehyde with a serial dilution of 25, 50,
250, 500, 5000 and 10 000 (1%) p.p.m. formalde-
hyde aqua. All 20 reacted to 10 000 p.p.m., 9 out
of 20 to 5000 p.p.m., 3 out of 20 to 1000 p.p.m.
(0.1%), 2 had a positive reaction down to 500 p.p.m.
and 1 patient was positive to 250 p.p.m. formalde-
hyde aqua (89). Retesting the patient reacting to 250
p.p.m. 1 year later with 50, 100 and 250 p.p.m.
showed a negative reaction.
In a similar study, 8 out of 35 formaldehyde
allergic subjects reacted with closed patch test-
ing down to 1000 p.p.m.; lower concentrations
were not tested (90). In a dose-ﬁnding study using
TRUE-test® materials, 5 out of 22 formaldehyde-
sensitive patients reacted to concentrations <630
p.p.m. with serial dilutions of formaldehyde and one
reacted down to 150 p.p.m. (91).
Use tests with formaldehyde-containing products
More important than the threshold for positive
patch test responses is to determine which con-
centrations of formaldehyde may cause eczematous
reactions when formaldehyde-containing products
are applied under normal use conditions. In the
above-mentioned studies of Jordan et al. (88), 11
formaldehyde-sensitive patients pump-sprayed 29
p.p.m. formaldehyde in a double-blind fashion from
a 12% methanol/water vehicle into one axilla twice
a day for 2 weeks. The vehicle served as a control in
the other axilla. Two of the patients developed very
mild perifollicular dermatitis to the formaldehyde
site but not the control site. It was concluded that
formaldehyde levels below 30 p.p.m. can be toler-
ated by most sensitive subjects if continually applied
to areas like the axilla (88). The threshold for no
response to a formaldehyde-containing antiperspi-
rant in another study was 80 p.p.m., patients were
reacting down to 150 p.p.m. (cited by (62). In
an old study involving one formaldehyde-sensitive
individual, ﬂare of vesicular hand eczema could be
provoked by immersing the ﬁnger in a 0.2 p.p.m.
formaldehyde solution for 40 min (92).
In various studies, repeated open application
tests (ROATs) have been performed with products,
usually cosmetic creams, containing varying con-
centrations of formaldehyde-releasers such as dia-
zolidinyl urea, quaternium-15, imidazolidinyl urea,
2-bromo-2-nitropropane-1,3-diol or DMDM hydan-
toin. The results of these studies are discussed in
another part of this systematic review. The lowest
concentrations of formaldehyde to which patients
reacted were 200–300 p.p.m. It should be realized
that most of these tests were conducted for a maxi-
mum of 1 week and on normal skin, usually on the
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2 weeks (or longer), applying the product to more
sensitive areas such as the axilla, the neck or the
face (12) may well result in more positive reactions
and/or lower thresholds for a positive response. This
may also be true for the situation where a product
is used on damaged skin, which is often done with
lubricants on dry or dermatitic skin.
Analytical tests to determine formaldehyde in
products
There are several tests to determine the formalde-
hyde content in products.
The chromotropic acid method. This semi-quantit-
ative method is based on a chemical reaction of
chromotropic acid and free formaldehyde giving a
violet discolouration. By comparing the intensity of
the sample colour with those of standards, a rough
estimation of the concentration of formaldehyde
can be obtained. Unfortunately, other aldehydes and
ketones can also react with chromotropic acid, giv-
ing yellow-brown discolorations that can interfere
with the test (93–95).
The acetylacetone method. In this semi-quantitative
method, formaldehyde reacts with acetylacetone
in the presence of ammonia to form the yel-
low compound 3,5-diacetyl-1,4-dihydrolutidine (this
method is sometimes also referred to as the lutidine
method) (96). The intensity of the yellow colour
can be compared with that of the standards to esti-
mate the content of formaldehyde in the sample.
If the product to be analysed is coloured itself,
an extraction procedure with 1-butanol can ﬁrst
be performed. Quantiﬁcation of the formaldehyde
concentration can be achieved by using an UV-
spectrophotometer (93, 96). This method was found
to be more efﬁcient for formaldehyde detection in a
clinical laboratory (94). In about 80% of the cases,
the results obtained with this test are similar to those
with the chromotropic acid method (95).
High performance liquid chromatography (HPLC).
This is a reliable method, of which various modiﬁ-
cations have been described (94, 97–100).
Ofﬁcial EU method. The EU has an ofﬁcial method
for determining total and free formaldehyde content
in cosmetic products (101). The total formalde-
hyde content determined by this method also rep-
resents the amount of formaldehyde that may be
available by the permitted formaldehyde-releasers,
except for 2-bromo-2-nitropropane-1,3-diol and 5-
bromo-5-nitro-1,3-dioxane, present in a product.
The analysis is performed in three steps in the
following sequence: identiﬁcation of formaldehyde,
spectrophotometric determination of total formalde-
hyde content in the products containing formalde-
hyde (based on the acetylacetone method) and
HPLC determination (employing post-column
derivatization) of free formaldehyde in the prod-
ucts that contain >0.05% total formaldehyde (101).
For a detailed description of this method see
Rastogi (37).
Tests for formaldehyde in clothing. The test most
frequently used for determining formaldehyde in
clothing is the American Association of Textile
Chemists and Colorists (AATCC) Test Method
112–1990, ‘Formaldehyde release from fabric,
sealed jar method’ (102, 103).
Tests for determining formaldehyde in the pres-
ence of formaldehyde donors. Quantiﬁcation of free
formaldehyde in the presence of formaldehyde
donors is problematic. With the commonly applied
methods, including the ofﬁcial EU method, the equi-
librium formaldehyde – formaldehyde donor – is
disturbed by the presence of the reagent, which
binds free formaldehyde. This leads to new release
of formaldehyde to maintain the equilibrium and
thus, such methods may give too high and non-
reproducible results. Quantitative 13C NMR spec-
troscopy is a purely physical method that does not
affect the equilibrium and offers and excellent solu-
tion to this problem (104).
Frequency of Exposure to Formaldehyde and
Formaldehyde-releasers
Data from Denmark: PROBAS database
The Danish Product Register Database (PROBAS)
was established in 1979. It is a governmental
database common for the authorities in the work-
ing environment and the external environment.
PROBAS in March 2009 contained information on
approximately 30 000 chemical products sold or
used in production in Denmark that have been noti-
ﬁed by their Danish or foreign enterprises The
main part of the registered products is notiﬁed
(declared) according to legal demands for provid-
ing information on hazardous chemical products
for occupational use. Other product categories are
included, but often do not cover all marketed prod-
ucts (e.g. cosmetics and toiletries). The registra-
tion includes information on chemical composition
with components identiﬁed by CAS numbers, dan-
ger labelling, product category, industrial area of use
and quantities imported or manufactured. The reg-
istered data are kept conﬁdential and public access
is not possible (105).
The legislation on notiﬁcation was changed in
July 2004. In short, the products to be notiﬁed were
extended to include most products covered by laws
demanding material safety data sheets. Furthermore,
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other year. For information on the chemical compo-
sition of products, a 1% limit was introduced. Thus,
only substances making up more than 1% of any
given product have to be declared. However, for
certain groups of substances, the limits are lower.
Preservatives, for example, must always be reported.
For toxic substances, carcinogens, mutagens and
reproductive toxicants, the limit is 0.1%. Substances
with lower limits in the EU list of toxic substances
or the EU directive on classiﬁcation should also be
declared (106). As these rules demand the name
of sensitizers to be declared on the label if the
content is above 0.1%, the lower limit for con-
tact allergens will be 0.1% (107). Further details on
PROBAS are provided in Flyvholm et al. (105) and
Flyvholm (108).
The data presented here include products regis-
tered by March 2009 which are active on the Danish
market and computerized with information on chem-
ical composition. All products containing the studied
substances either directly or from raw materials are
included. Data on substances notiﬁed by less than
three companies were excluded.
Formaldehyde (releasers) in PROBAS. Table 6 pro-
vides the PROBAS data on formaldehyde and
formaldehyde-releasers. For each chemical, the fol-
lowing data are tabulated: total number of registered
products containing it, number of products per prod-
uct category containing the chemical plus percent-
age, use volume of each chemical and each category
in tonnes/year, and product category speciﬁcation.
Formaldehyde was registered in 2363 products
with a total volume of 26 153 tonnes per year.
The main product categories by volume were
raw materials and intermediate products (25 967
tonnes) followed by biocides/pesticides for non-
agricultural uses (659 tonnes). By number of
products, paints/lacquers/varnishes were the most
frequently registered product categories for formal-
dehyde (n = 1306), followed by cleaning agents
(n = 222).
The highest volumes of registered use of formald-
ehyde-releasers were scored by polyoxymethylene
urea (7596 tonnes) and tris(N-hydroxyethyl) hex-
ahydrotriazine (1709 tonnes). By number of regis-
tered products, the most frequent were 2-bromo-2
-nitropropane-1,3-diol (n = 549), 1,6-dihydroxy-2,
5-dioxahexane (n = 289) and polyoxymethylene
urea (n = 182).
The most important product categories contain-
ing formaldehyde or formaldehyde-releasers are
biocides/pesticides, paints/lacquers/varnishes, clean-
ing/washing agents and metalworking ﬂuids (cool-
ing agents for metal processing) (Table 6).
Nineteen of the 42 formaldehyde-releasers could
not be found in PROBAS. In most cases, e.g.
the formaldehyde-releasers used as durable press
chemical ﬁnishes, they are used in products (in
this example clothes and textiles) not covered by
the database because Danish law does not require
their notiﬁcation in PROBAS. This also explains
why the numbers of registered products containing
typical cosmetics preservatives such as quaternium-
15, imidazolidinyl urea and diazolidinyl urea are
so low: only a very limited number of cosmetics
are registered in PROBAS. The same holds true
for some other releasers such as Bioban® CS 1135
and Bioban® P-1487, which are reportedly used in
metalworking ﬂuids. These need not to be notiﬁed
and their absence in PROBAS, therefore, does not
indicate that they are actually not used in such
cooling agents for metal processing.
The data on the occurrence of formaldehyde and
formaldehyde-releasers in registered chemical prod-
uct should be interpreted with caution. Thus, when
formaldehyde and formaldehyde-releasers are regis-
tered in a particular product category, this can form
an important part of an exposure assessment. How-
ever, when no registration is found for a certain
product type, it cannot be concluded that this partic-
ular category will not contain the allergen. Products
for ‘private consumer use only’, for example, are
not registered in PROBAS at all.
Other data on exposure to formaldehyde and
formaldehyde-releasers
In 1992, 161 rinse-off products and 124 leave-on
products produced in various European countries
and the USA were investigated in Denmark for the
presence of formaldehyde. 30% proved to contain
(free and bound) formaldehyde (37). In the same
year, in Switzerland, 34 cosmetic products were
investigated for the presence of formaldehyde using
three analytical methods including HPLC. Nineteen
products (56%) were found to contain free formalde-
hyde (43). A 1993 study of washing and cleaning
agents showed that formaldehyde-releasing com-
pounds were among the most commonly registered
preservatives in such products (36). In 1998, 100
moisturizers sold in Sweden were analysed for the
presence and amount of preservatives. Thirty-ﬁve
products contained a formaldehyde-releaser. Ten
products contained more than 200 p.p.m. formalde-
hyde; in nine of these a formaldehyde-releaser
was present. The concentrations of the releasers
did not exceed the EU-permitted maximum in any
case (109).
In the USA, imidazolidinyl urea was present in
13.0%, DMDM hydantoin in 5.0%, quaternium-15
in 3.7%, diazolidinyl urea in 3.6% and formaldehyde
per se as a preservative in <1% of approximately
20 000 formulae registered with the FDA in 1996.
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Table 6. Presence of formaldehyde and formaldehyde releasers in chemical products registered in the Danish Product Register Database,
March 2009 as active on the market. Data on substances notiﬁed by less than three companies are not shown.∗
Number of Percentage
registered of products Volume
Chemical products in category Tonnes/year Product category
Formaldehyde 2363 26152.95
56 5.38 103.11 Adhesives
63 10.59 8.31 Binding agents - for binding together the individual
constituents in the product
51 4.59 658.52 Biocides - pesticides for non agricultural uses
222 5.37 0.53 Cleaning/washing agents
46 7.67 0.01 Colouring agents
46 8.42 21.04 Construction materials (building materials)
7 2.27 0.00 Cooling agents for metal processing
12 3.72 0.01 Cosmetics
79 6.86 6.49 Filling agents
11 31.43 1.22 Fixing agents - for ﬁxing chemicals/particles to
surfaces and ﬁbres (not photo chemicals).
18 10.34 0.08 Flooring materials (joint-less ﬂoors)
10 7.04 0.00 Galvano-technical agents - for metal surface treat-
ment
59 76.62 0.01 Glazing materials, enamels etc.
5 1.52 0.05 Hardeners
18 9.18 3.04 Impregnation/ prooﬁng - for protection from damp,
fungus etc.
3 2.46 0.00 Insulating materials - to protect from noise, cold,
electricity, dust etc.
41 10.00 2.49 Laboratory chemicals
5 0.35 0.00 Lubricants
12 2.44 4.99 Metal surface treatment remedies
7 5.11 9.65 Moulding compounds
3 1.57 0.00 Paint and varnish removers
1306 22.53 2.97 Paint, lacquers and varnishes
2 1.17 0.02 pH-regulating agents
6 1.82 0.04 Plant protection - agricultural pesticides
15 3.00 0.02 Polishing agents
58 11.26 0.02 Printing inks
6 1.01 0.04 Process regulators (synthesis regulators)
14 2.36 25967.47 Raw materials and intermediate products
3 2.14 0.00 Rinsing agents
22 4.31 0.08 Rust inhibitors
3 2.22 0.12 Sanitation agents - for cleaning up liquids and
other materials
8 15.38 0.03 Sequestering agents
4 5.56 0.06 Softeners (plastic-, rubber-, paint-, adhesive soft-
eners)
14 7.57 0.02 Surface treatment for paper, cardboard and other
non-metals
16 2.40 0.33 Surface-active agents - (surfactants, detergents)
35 39.33 1.50 Toners
8 10.67 0.01 Writing agents
Benzylhemiformal 87 0.85
3 0.97 0.03 Cooling agents for metal processing
65 1.12 0.01 Paint, lacquers and varnishes
Bioban CS 1246® 16 0.19
7 2.27 0.18 Cooling agents for metal processing
2-Bromo-2-nitropropane-1,3-diol 549 69.84
27 2.59 0.10 Adhesives
11 1.85 0.13 Binding agents - for binding together the individual
constituents in the product
22 1.98 43.34 Biocides - pesticides for non agricultural uses
111 2.69 0.70 Cleaning/washing agents
8 1.33 0.01 Colouring agents
7 1.28 0.00 Construction materials (building materials)
19 5.88 0.14 Cosmetics
13 1.13 0.00 Filling agents
15 7.65 0.10 Impregnation/ prooﬁng - for protection from damp,
fungus etc.80 DE GROOT ET AL. Contact Dermatitis 2009: 61: 63–85
Table 6. (Continued)
Number of Percentage
registered of products Volume
Chemical products in category Tonnes/year Product category
204 3.52 19.17 Paint, lacquers and varnishes
18 3.60 0.02 Polishing agents
18 3.50 0.10 Printing inks
5 2.70 0.00 Surface treatment for paper, cardboard and other
non-metals
13 1.95 0.03 Surface-active agents - (surfactants, detergents)
5 4.03 0.01 Viscosity adjustors
5-Bromo-5-nitro-1,3-dioxane 62 0.47
25 0.61 0.14 Cleaning/washing agents
24 7.43 0.21 Cosmetics
5 1.00 0.00 Polishing agents
Diazolidinyl urea 4 0.10
1,6-Dihydroxy-2,5-dioxahexane 289 26.13
5 0.48 0.01 Adhesives
10 0.90 24.85 Biocides - pesticides for non agricultural uses
13 0.31 0.01 Cleaning/washing agents
11 1.83 0.00 Colouring agents
5 1.62 0.39 Cooling agents for metal processing
8 0.69 0.01 Filling agents
174 3.00 0.22 Paint, lacquers and varnishes
15 2.91 0.50 Printing inks
3 1.62 0.00 Surface treatment for paper, cardboard and other
non-metals
4 0.60 0.01 Surface-active agents - (surfactants, detergents)
Dimethylol urea 78 7.50
2 0.34 0.00 Binding agents - for binding together the individual
constituents in the product
3 0.27 7.36 Biocides - pesticides for non agricultural uses
10 0.24 0.00 Cleaning/washing agents
25 0.43 0.06 Paint, lacquers and varnishes
DMDM hydantoin 16 0.14
Imidazolidinyl urea 3 0.00
Melamine/formaldehyde resin 98 162.29
57 0.98 53.25 Paint, lacquers and varnishes
Methenamine 117 99.27
3 0.29 0.04 Adhesives
17 1.53 0.28 Biocides - pesticides for non agricultural uses
10 0.24 0.06 Cleaning/washing agents
3 0.61 0.02 Metal surface treatment remedies
49 0.85 0.08 Paint, lacquers and varnishes
3 0.59 0.11 Rust inhibitors
Methylal 91 35.44
13 0.31 1.04 Cleaning/washing agents
11 0.76 2.77 Lubricants
3 1.57 1.77 Paint and varnish removers
N,N’-Methylenebis(5-methyloxazolidine) 36 11.06
5 0.45 8.45 Biocides - pesticides for non agricultural uses
20 6.49 1.76 Cooling agents for metal processing
4,4’-Methylenedimorpholine 18 5.13
11 3.57 4.66 Cooling agents for metal processing
N-Methylolchloracetamide 83 0.07
4 0.67 0.00 Binding agents - for binding together the individual
constituents in the product
3 0.26 0.01 Filling agents
47 0.81 0.01 Paint, lacquers and varnishes
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Table 6. (Continued)
Number of Percentage
registered of products Volume
Chemical products in category Tonnes/year Product category
N-Methylolethanolamine 33 2.34
8 2.60 2.08 Cooling agents for metal processing
19 0.33 0.08 Paint, lacquers and varnishes
Paraformaldehyde 8 1.50
Polyoxymethylene urea 182 7595.94
13 1.25 1122.75 Adhesives
148 2.55 56.49 Paint, lacquers and varnishes
Quaternium-15 30 0.05
11 3.41 0.00 Cosmetics
Sodium hydroxymethylglycinate 60 1.72
48 1.16 0.90 Cleaning/washing agents
4 2.86 0.03 Rinsing agents
Tetramethylol acetylene diurea 100 1.70
7 1.17 0.07 Colouring agents
7 0.61 0.03 Filling agents
66 1.14 1.58 Paint, lacquers and varnishes
6 1.20 0.01 Polishing agents
3 1.62 0.01 Surface treatment for paper, cardboard and other
non-metals
Tris(hydroxymethyl)-nitromethane 84 0.19
13 0.31 0.08 Cleaning/washing agents
40 0.69 0.08 Paint, lacquers and varnishes
2 1.48 0.01 Sanitation agents - for cleaning up liquids and
other materials
Tris(N-hydroxyethyl) hexahydrotriazine 103 1708.54
7 0.63 1.02 Biocides - pesticides for non agricultural uses
9 0.22 0.05 Cleaning/washing agents
11 3.57 0.97 Cooling agents for metal processing
5 0.35 3.10 Lubricants
41 0.71 3.47 Paint, lacquers and varnishes
4 0.78 0.02 Printing inks
3 0.59 0.04 Rust inhibitors
Total 3560 12.10 40125.11
∗Cosmetics and metalworking ﬂuids do not need to be notiﬁed by legal demand. Therefore, the data for these product categories are not
representative for the Danish market.
most frequently used cosmetic preservatives after
methyl- and propylparaben, DMDM hydantoin sev-
enth, quaternium-15 ninth and diazolidinyl urea
tenth (110). In 2003, the most frequently used
formaldehyde donor was – again – imidazolidinyl
urea (present in 2038 products), followed by DMDM
hydantoin (993 products), diazolidinyl urea (725
products), quaternium-15 (516 products) and
2-bromo-2-nitropropane-1,3-diol (168 products).
Formaldehyde per se as a preservative was present
in only 118 products. It was not stated what the total
number of cosmetic products registered at the FDA
was in 2003 (111).
In 2000, Rastogi in Denmark analysed preser-
vatives in 67 skin creams to verify the data on
the product labels. Five (7%) contained 2-bromo-
2-nitropropane-1,3-diol, none 5-bromo-5-nitro-1,3-
dioxane and 34 (51%) contained formaldehyde,
either from formaldehyde-releasers or from its pres-
ence per se (80).
Discussion
The main subject of this literature study is the
relationship between formaldehyde-releasers and
sensitivity to formaldehyde. In this part of our
four-part review, we have identiﬁed the curren-
tly known – and alleged – formaldehyde-releasers
(Table 2). They are discussed in detail in the other
parts of this review. Therefore, the discussion here
is limited to some aspects of formaldehyde contact
allergy.
It is remarkable that the frequency of sensitiza-
tion to formaldehyde in the USA has consistently
been (much) higher than in European countries for
the past 20 years. The regularly reported ongoing
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prevalence rates of 7.8% in 1992–1994 (76), 9.2%
in 1994–1996 (73), 9.3% in 1996–1998 (71), 9.2%
in 1998–2000 (68) and 8.4% in 2001–2002 (62).
These ﬁgures are paralleled by data from other
USA clinics: 6.8% (1988–1997, Boston, Albert
et al. (9)), 7.9% (1998–2000 Mayo Clinic, Wetter
et al. (67)) and 9.0% (2001–2005, Mayo Clinic,
Davis et al. (55)). In most European countries,
prevalence rates vary between 2% and 3% (Table 5),
and in the recent multicentre European investiga-
tions performed by the European Environmental and
Contact Dermatitis Research Group (EECDRG) and
the European Surveillance System on Contact Aller-
gies (ESSCA), prevalence rates were between 2.0%
and 2.3% (59, 60, 65). These ﬁgures, both from the
USA and from Europe, thus seem to be reproducible
and real. With the current knowledge, the causes of
such major differences are not readily found. This
topic will be dealt with separately.
Patch testing with formaldehyde is problematic.
Former test concentrations of 3–5% resulted in
many false-positive reactions. Currently, 1% aqua
is the standard for patch testing. However, there
are indications that this concentration is too low,
resulting in (many) false-negative reactions: of 98
patients with an allergic reaction to formaldehyde
2% aqua, only 59 (60%) reacted to the currently
used formaldehyde 1% aqua (46). This may indicate
that up to 40% of allergic patients are missed when
tested with formaldehyde 1% aqua only (46). We
suggest that further research into this matter be done
to clarify this important issue.
Determining the relevance of a positive reac-
tion to formaldehyde is another challenging prob-
lem for the dermatologist. The use of formaldehyde
and formaldehyde-releasers is widespread in cos-
metics, toiletries, household products and industry.
With current mandatory labelling in the USA and
the EU, the presence of formaldehyde (releasers)
in cosmetics is relatively easy to establish. How-
ever, this does not apply to household and indus-
trial products∗. The presence of free formaldehyde
in concentrations over 0.05% (500 p.p.m.) must be
declared on the label of such products, but it has
been shown convincingly that exposure to lower lev-
els may induce allergic contact dermatitis (12, 88,
112). Conversely, the fact that a product is labelled
to contain formaldehyde or a formaldehyde-releaser
does not implicitly mean that it is harmful to the
formaldehyde-sensitive patient, as the concentration
of free formaldehyde may well be below the elicita-
tion threshold for the particular patient. From the
∗The Detergents Regulations 648/2004 of the European Union
came into force in October 2005 and requires the listing of preser-
vation agents irrespective of their concentration in products for domes-
tic use. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:
2006:168:0005:0010:EN:PDF
formula it cannot be determined how much free
formaldehyde is present.
To complicate things further, a patient is usually
exposed to many products containing free formalde-
hyde that may separately not pose a threat, but when
used in combination or sequentially this may break
through the threshold for elicitation of allergic con-
tact dermatitis. Therefore, only rarely – in the case
of formaldehyde sensitivity – can a clear-cut rela-
tionship can be established between the use of a
particular product and induction or exacerbation of
dermatitis, thereby ascertaining relevance. Indeed,
in the NACDG studies, the percentages of patients
with ‘possible relevance’ far exceeded that of the
percentage for ‘deﬁnite/probable relevance’ (62, 68,
73). The difﬁculty of ﬁnding relevant products is
also attested by the fact that even in patients actively
trying to avoid products containing formaldehyde,
the dermatitis will infrequently heal completely.
Most patients will still suffer from exacerbations of
dermatitis (81, 84, 87).
What concentration of formaldehyde is safe for
sensitive patients remains, even though several
investigations have addressed this issue, largely
unknown. There is a lack of eliciting threshold
data based on systematic investigations and an
obvious need for experimental studies illustrat-
ing the relevance of formaldehyde exposure in a
dose–response manner on healthy and diseased skin
in formaldehyde-sensitive individuals (46).
Levels of 200–300 p.p.m. free formaldehyde in
cosmetic products have been shown to induce der-
matitis from short-term use on normal skin. It may
be assumed that thresholds of elicitation are lower
when these or other topical products are used on
more sensitive skin (e.g. the axillae), for longer
periods of time or on diseased skin. This demon-
strates beyond doubt that EU legislation, stipulating
that all ﬁnished products containing >500 p.p.m.
free formaldehyde must be labelled with the warn-
ing ‘contains formaldehyde’, is not strict enough
and the concentration required for the labelling
should be lowered. We suggest that more exten-
sive use test studies with formaldehyde-containing
products in formaldehyde-sensitive studies be per-
formed to determine a ‘no-effect level’ for elicitation
of allergic contact dermatitis from single product
usage.
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